Innovative drug discovery information platform 'Design Hub'
Design HUB is a groundbreaking information platform that integrates hypothesis-driven and data-driven approaches to streamline the DMTA cycle in drug discovery.
Design HUB is a groundbreaking information platform that integrates "hypothesis-driven" and "data-driven" approaches to streamline the DMTA (Design, Make, Test, Analyze) cycle in the early stages of drug discovery. It also functions as a content hub, enhancing the efficiency and success rate of the entire drug discovery process. Furthermore, it provides secure information-sharing capabilities to facilitate collaboration with external CROs and universities, supporting the efficient advancement of project tasks. **Features** - **Compound Design and Real-Time Analysis** - Can be used as a personal workstation or for brainstorming among multiple scientists - Displays real-time information on the properties of drawn structures and known similar compounds - Rapidly reviews ideas through comparisons and filtering with existing compound library data, as well as examining pharmacophore models by drawing three-dimensional structures *For more details, please refer to the PDF materials or feel free to contact us.*
basic information
【Other Features】 <Integration of External Resources> ■ Customizable plugins based on JavaScript and a wealth of templates ■ Data integration with any service via REST, SQL, or CLI methods <Management of Ideas and Projects> ■ Organize and manage original data and discussion content by hypothesis ■ Save data used for analysis during the structural optimization phase as a design set ■ Visualize who is responsible for what and the progress status using a Kanban board *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Model number/Brand name
ChemAxon Design Hub: Design Hub
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Related Videos
catalog(6)
Download All CatalogsNews about this product(3)
-
Chemaxon announces the appointment of its new CEO, Richard Jonas.
Chemaxon, a leader in the development of cheminformatics software for life sciences research, has announced the appointment of Richard Jones as Chief Executive Officer (CEO). Richard succeeds the owner, Ferenc (Csizi) Csizmadia, in this role. Csizi will continue to serve as a founder while focusing on the establishment of Ancestralize, which is centered on health and well-being in the digital age. Additionally, coinciding with Mr. Richard's appointment, Chemaxon's Budapest office has relocated to the newly constructed environmentally friendly office park, Váci Greens, on the east side of the Danube River. A new logo and spelling have also been announced. For more details, please visit the news article on our company's homepage via the link below.
-
Chemical.AI and Chemaxon announce collaboration in the integration of scientific information software.
Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.
-
Screening of commercial compounds in drug discovery
"Can even new drugs be discovered from commercially available compounds?" The size of the drug-like chemical space is estimated to be about 10^63 molecules. It is expected that future drugs will be found somewhere in this vast space. To enable chemists to easily access this chemical space, several compound vendors are building commercial databases of available compounds or drug-like compounds that are predicted to have a high likelihood of being synthesized. Many pharmaceutical companies are also building their own databases. ChemAxon provides access to various databases through its compound design platform "Design Hub," and we have compiled this information into a white paper, so please take a look.